Mylan, Theravance win FDA approval for COPD drug

Theravance Biopharma and Mylan on Friday picked up approval for Yupelri for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The thumbs up came a few days ahead of the inhaled therapy's Nov. 13 Prescription Drug User Fee Act date